首页> 美国卫生研究院文献>Kidney Research and Clinical Practice >A randomized crossover study of single biweekly administration of epoetin-α compared with darbepoetin-α in chronic kidney disease patients not receiving dialysis
【2h】

A randomized crossover study of single biweekly administration of epoetin-α compared with darbepoetin-α in chronic kidney disease patients not receiving dialysis

机译:在未接受透析的慢性肾脏病患者中单次双周施用epoetin-α和darbepoetin-α的随机交叉研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundRecent evidence demonstrates that high doses of epoetin-alpha (EPO-α) can be administrated at extended intervals, despite its relatively short serum half-life. However, no prospective randomized trials on the effects of extended dosing intervals of EPO-α compared with darbepoetin-alpha (DA-α) have been performed. This study was designed to investigate whether a single biweekly (Q2W) administration of a high dose of EPO-α is as effective as DA-α for anemia in chronic kidney disease (CKD) patients not receiving dialysis.
机译:背景技术最近的证据表明,尽管血清半衰期相对较短,但仍可以延长间隔服用高剂量的依泊汀-α(EPO-α)。但是,尚未进行与darbepoetin-α(DA-α)相比延长的EPO-α给药间隔影响的前瞻性随机试验。这项研究旨在调查在不接受透析的慢性肾脏病(CKD)患者中,每两周一次(Q2W)高剂量的EPO-α贫血是否与DA-α一样有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号